High‐Sensitivity Cardiac Troponin I and T Response Following Strenuous Activity is Attenuated by Smokeless Tobacco: NEEDED (North Sea Race Endurance Exercise Study) 2014
Open Access
- 6 October 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Heart Association
- Vol. 9 (19)
- https://doi.org/10.1161/jaha.120.017363
Abstract
Background Use of snus, a smokeless tobacco product, is increasing in Scandinavia. Strenuous physical activity is associated with an acute increase in high‐sensitivity cardiac troponin (swhs‐cTn) concentrations. Current smoking is associated with lower hs‐cTn, but whether this also holds true for smokeless tobacco and whether tobacco affects the hs‐cTn response to exercise remain unknown. Methods and Results We measured hs‐cTnI and hs‐cTnT concentrations in 914 recreational athletes before and 3 and 24 hours after a 91‐km bicycle race. Self‐reported snus tobacco habits were reported as noncurrent (n=796) and current (n=118). The association between snus use and change in log‐transformed hs‐cTnI and hs‐cTnT concentrations (ie, the differences between concentrations at baseline and 3 hours and 24 hours ) were assessed by multivariable linear regression analysis. Concentrations of hs‐cTn at baseline were lower in current than in noncurrent snus users (hs‐cTnI median, 1.7 ng/L; Q1 to Q3: 1.6–2.3 versus 2.0 ng/L; Q1 to Q3: 1.6–3.2 [P=0.020]; and hs‐cTnT: median, 2.9 ng/L, Q1 to Q3: 2.9–3.5 versus 2.9 ng/L, Q1 to Q3: 2.9–4.3 [P=0.021]). In fully adjusted multivariable models, use of snus was associated with lower change in hs‐cTn concentrations from baseline to 3 hours (hs‐cTnI: −29% [P=0.002], hs‐cTnT: −18% [P=0.010]) and 24 hours (hscTnI: −30% [P=0.010], hs‐cTnT −19%, [P=0.013]). Conclusions Resting hs‐cTn concentrations are lower and the exercise‐induced cardiac troponin response is attenuated in current users of smokeless tobacco compared with nonusers. Further insight into the pathophysiological processes underlying the attenuated cardiac troponin response to exercise in tobacco users is needed. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT02166216.This publication has 35 references indexed in Scilit:
- Impact of Smokeless Tobacco Products on Cardiovascular Disease: Implications for Policy, Prevention, and TreatmentCirculation, 2010
- Nicotine AddictionThe New England Journal of Medicine, 2010
- Are current smokers paradoxically protected against atrial fibrillation after cardiac surgery?Nicotine & Tobacco Research, 2009
- Free nicotine content and strategic marketing of moist snuff tobacco products in the United States: 2000-2006Tobacco Control, 2008
- Hemodynamic and autonomic effects of smokeless tobacco in healthy young menJournal of the American College of Cardiology, 2005
- Role of Risk Factors in the Modulation of Tissue Factor Activity and Blood ThrombogenicityCirculation, 2003
- Smoking and mortality following acute myocardial infarction: results from the National Registry of Myocardial Infarction 2 (NRMI 2)Nicotine & Tobacco Research, 2002
- Acute effects of cigarette smoking on platelet-dependent thrombin generationEuropean Heart Journal, 2001
- Pharmacokinetics and pharmacodynamics of moist snuff in humansTobacco Control, 1999
- Relationship of cigarette smoking and snuff dipping to plasma fibrinogen, fibrinolytic variables and serum insulin. The Northern Sweden MONICA studyAtherosclerosis, 1995